Phase 2 Breast Cancer Trial, Recruiting NCT06165900 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06165900
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 to 75 years who have not yet received any treatment for breast cancer
  • People with a confirmed diagnosis of early or locally advanced triple-negative breast cancer (a specific type where the cancer tests negative for oestrogen receptors, progesterone receptors, and HER2), confirmed through a tissue sample analysis
  • People with stage II or III invasive breast cancer that has at least one measurable tumour
  • People with a good general health and activity level (rated 0 or 1 on a standard health scale used in clinical trials)
  • People assessed by a radiation specialist as able to safely receive radiotherapy before and after surgery
  • People with adequate organ function (confirm with trial site for specific requirements)
  • People who are willing to participate, have signed a consent form, and are expected to follow the study requirements

Who may not be able to join:

  • People whose breast cancer has spread to other parts of the body, or who have cancer in both breasts
  • People with inflammatory breast cancer or a type of breast cancer with no detectable primary tumour in the breast
  • People who have received any cancer treatment in the 12 months before joining the trial, including chemotherapy, targeted therapy, radiotherapy, hormone therapy, immunotherapy, biological therapy, or tumour embolisation
  • People who have previously been treated with certain immune checkpoint drugs, including PD-1, PD-L1, or CTLA-4 blocking treatments
  • People who are pregnant, breastfeeding, have a positive pregnancy test at the start of the trial, or are of childbearing age and are unwilling to use effective contraception throughout the trial
  • People with a known history of neurological or psychiatric conditions such as epilepsy or dementia, or a known history of alcohol dependence or misuse of mind-altering substances
  • People with HIV, AIDS, or certain active viral hepatitis infections (including hepatitis B or hepatitis C, confirmed through specific blood tests)
  • People who, in the opinion of the trial investigators, have any other condition that makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 18940254967

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
26 September 2023
Est. completion
15 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

tpCR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov